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of	 Clinical	 Trials	 Research,	 University	 of	 Leeds,	 Leeds;	
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to	 the	study.	 	This	 revealed	seven	phase	 I/II	 trials	specifically	 for	patients	with	myeloma,	 including	
investigation	of	panobinostat	as	monotherapy	and	in	combination	with	melphalan	prednisolone	and	
thalidomide.	 	 A	 number	 of	 other	 HDAC	 inhibitors	 were	 also	 investigated;	 however,	 none	 of	 them	




for	patients	with	 relapsed	myeloma.	Since	 this	 trial	 started	 there	had	been	 further	publications	 to	
that	 described	 above.	 	 The	 included	 the	 pivotal	 phase	 III	 trial	 (PANORAMA	 2)	 of	 bortezomib	
(Velcade),	dexamethasone	plus	panobinostat	(VD-P)	versus	bortezomib	dexamethasone	and	placebo	
for	relapsed	myeloma.		A	separate	publication	of	the	predefined	sub-set	analysis	led	to	panobinostat	
approval	 in	 the	US	and	Europe.	Other	published	 trials	 included	VD-P	 for	newly	diagnosed	patients	
which	 was	 halted	 due	 to	 a	 lack	 of	 efficacy	 and	 increased	 toxicity	 (used	 bi-weekly	 intravenous	
bortezomib),	a	Phase	I/II	of	panobinostat	with	carfilzomib	and	dexamethasone	and	the	phase	I	study	
to	 determine	 the	 recommended	 dose	 of	 panobinostat	 for	 bortezomib	 combinations.	 The	
PANORAMA	 1	 phase	 II	 trial	 (VD-P)	 reported	 the	 efficacy	 of	 VD-P	 in	 patients	 with	 relapsed	 and	
bortezomib	refractory	myeloma	with	a	response	rate	of	34·5%.		However,	the	VD-P	regimen	in	the	





Panobinostat	 represents	 a	 new	 class	 of	 anti-myeloma	 therapy	 that	 has	 gained	 FDA	 and	 EMEA	
approval	 for	 patients	 following	 two	 or	 more	 prior	 lines	 of	 therapy	 including	 bortezomib	 and	 an	
immunomodulatory	agent.	This	was	based	on	the	sub-group	analysis	of	the	phase	III	PANORAMA	2	
trial.	The	MUK-six	trial	predominantly	included	patients	at	first	relapse	and	adds	to	the	evidence	that	






dexamethasone	 is	approved	 for	patients	with	 relapsed	multiple	myeloma	 (MM).	The	MUK	six	 trial	









cycles	 of	 VTD-P	 then	 up	 to	 one	 year	 panobinostat	 maintenance.	 www.clinical	 trials.gov	
(NCT02145715),	ISRCTN59395590.	
Findings:	 57	 patients	 were	 enrolled	 with	 a	 median	 of	 one	 prior	 lines	 of	 therapy	 (80·2%	 at	 first	
relapse).	 46	 were	 treated	 at	 the	 RD	 (intention-to-treat	 population).	 One	 dose	 limiting	 toxicity	 was	
reported,	 hence	 the	 MTD	 was	 not	 reached	 and	 the	 RD	 of	 panobinostat	 was	 20mg.	 The	 overall	
response	rate	(primary	endpoint)	was	91·3%	(95%	CI	79·2%-97·6);	CR	3(6·5%),	VGPR	18	(39·1%),	PR	













Proteasome	 inhibitor	 and	 immunomodulatory	 (IMiD)	 agents	 have	 become	 standard	 therapy	 for	
patients	 with	 multiple	 myeloma	 (MM).	 The	 combination	 of	 these	 two	 classes	 of	 drugs	 is	 highly	




at	 relapse	 achieving	 ≥	 partial	 response	 (PR)	 rates	 of	 63%
4
.	 Panobinostat	 (P),	 a	 pan	 histone	
deacetylase	 (HDAC)	 inhibitor	 was	 recently	 licensed	 in	 combination	 with	 bortezomib	 and	





progression-free	 survival	 (PFS)	 (12·5	 vs	 4·7	 months)	 to	 those	 receiving	 placebo,	 they	 also	






We	 therefore	 designed	 the	 MUK	 six	 trial	 to	 improve	 the	 tolerability	 of	 the	 VD-P	 combination	 and	







MUK	 six	 was	 a	 multi-centre	 open	 label	 phase	 I/II	 trial	 run	 through	 the	 Myeloma	 UK	 Clinical	 Trials	
Network,	for	patients	with	relapsed	or	relapsed/	refractory	MM	who	had	received	between	one	and	
four	 prior	 lines	 of	 therapy.	 Patients	 ≥18	 years	 were	 eligible	 with	 measureable	 disease,	 an	 Eastern	






function.	 Exclusion	 criteria	 included	 anti-myeloma	 therapy	 within	 28	 days	 of	 treatment	 (except	
dexamethasone	 160mg	 >48	 hours	 prior	 to	 treatment),	 refractory	 to	 bortezomib	 as	 per	 consensus	



















response	 plus	 two	 cycles	 (minimum	 six).	 Those	 completing	 16	 cycles	 of	 VTD-P	 could	 receive	
panobinostat	 monotherapy	 (at	 the	 same	 dose	 as	 the	 current	 dosing	 level	 or	 escalated	 to	 a	 level	
deemed	safe	using	the	same	schedule	as	induction)	for	up	to	one	year.	Those	undergoing	ASCT	were	




	 (Figure	1)	was	used	 to	determine	 the	MTD	of	panobinostat	beginning	at	dose	
level	 1	 and	 dose	 limiting	 toxicities	 (DLTs)	 assessed	 during	 the	 first	 21	 days	 of	 VTD-P.	 The	 Dose	
Escalation	Review	Group	(DERG),	comprising	all	principal	investigators	and	at	least	one	independent	
member,	 reviewed	 safety	 data	 throughout	 and	 decided	 cohort	 dose	 escalations.	 The	 RD	 was	 the	







Dose	 delays	 and	 modifications	 were	 as	 per	 trial	 protocol	 (see	 Supplementary	 material).	 Response	









from	 CD138	 selected	 cells	 according	 to	 local	 practice.	 Adverse	 Fluorescence	 in	 situ	 hybridization	






deemed	sufficient	 to	estimate	activity	of	 the	RD	 (≥PR).	This	gave	80%	power	 to	observe	at	 least	a	
78%	response	rate	and	rule	out	a	rate	of	<63%	at	the	1-sided	10%	significance	level	using	A’Hern’s	
exact	 single	 stage	 design
11




Safety	data	 is	for	all	 that	received	at	 least	one	dose	of	any	trial	treatment	(safety	population).	The	
primary	 analysis	 population	 to	 determine	 the	 RD	 of	 panobinostat	 was	 initially	 defined	 as	 patients	







There	 was	 no	 formal	 statistical	 testing.	 Percentages	 were	 calculated	 using	 the	 total	 number	 of	
patients	in	the	appropriate	population	as	the	denominator.	Confidence	intervals	(CI)	were	calculated	
using	 the	 Clopper-Pearson	 method,	 PFS	 and	 time	 to	 maximum	 response	 used	 the	 Kaplan	 Meier	
method.	 ASCT	 patients	 were	 censored	 at	 time	 of	 ASCT	 for	 primary	 PFS	 analysis	 and	 sensitivity	
analyses	performed.	
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escalation	 phase	 comprised	 16	 patients.	 Seven	 were	 registered	 to	 the	 10mg	 cohort	 with	 six	
evaluable	 for	 DLTs;	 three	 patients	 registered	 to	 the	 15mg	 cohort,	 all	 evaluable	 for	 DLTs;	 and	 six	
patients	 registered	 to	 the	 20mg	 cohort	 and	 evaluable	 for	 DLTs	 (Figure	 2).	 There	 was	 one	 DLT	 of	
grade	 3	 hyponatremia	 (unrelated	 to	 study	 drugs,	 due	 to	 high	 paraprotein)	 reported	 at	 20mg	 of	
panobinostat	and	consequently	the	MTD	of	panobinostat	was	not	reached.	The	RD	of	panobinostat	
was	taken	at	20mg.	
The	 ITT	 population	 comprised	 46	 patients	 treated	 at	 the	 RD,	 and	 the	 evaluable	 population	 39	




approval	 population).	 Patients	 received	 a	 median	 of	 10	 cycles	 of	 treatment	 and	 24	 patients	 (51%)	
came	 off	 study	 following	 a	 median	 of	 8	 (range	 6-16)	 cycles	 to	 proceed	 to	 ASCT.	 Twenty	 (35·1%)	
patients	 completed	 16	 cycles	 and	 15	 (26·3%)	 received	 panobinostat	 maintenance.	 Nine	 (15·8%)	
stopped	study	treatment	due	to	disease	progression,	one	died	on	study	due	to	an	unrelated	event	
(sickle	 cell	 crisis)	 and	 3	 (5·3%)	 withdrew	 consent	 due	 to	 toxicity.	 At	 the	 time	 of	 final	 analysis	 six	
patients	 had	 died:	 two	 due	 to	 MM,	 two	 due	 to	 unspecified	 abdominal	 causes,	 one	 due	 to	
cerebrovascular	disease	and	another	from	a	secondary	malignancy.	
The	 overall	 response	 rate	 for	 patients	 treated	 at	 the	 RD	 (ITT	 population	 n=46)	was	91·3%	 (95%	CI	
79·2-97·6);	Table	3	 shows	breakdown	by	maximum	response	and	varying	subgroups.	The	depth	of	
response	was	higher	for	those	treated	at	first	relapse	than	those	at	later	stages	(≥VGPR:	1	prior	line,	
54·7%	 (n=37)	 vs	 >1	 prior	 line,	 11·1%	 (n=9)),	 and	 lower	 for	 those	 in	 the	 EMA	 approval	 population	
(≥VGPR	 12·5%	 (n=8)	 vs	 52·6%	 (n=38).	 Responses	 were	 similar	 according	 to	 prior	 bortezomib	
exposure	 (≥VGPR:	 	 45·5%	 (n=33)	 vs	 46·2%	 (n=13))	 and	 slightly	 lower	 with	 prior	 IMiD	 exposure	 (≥	
VGPR	37·5%	(n=24)	vs	54·5%	(n=22)).	VGPR	and	above	rates	were	slightly	lower	for	those	with	one	or	
more	 adverse	 FISH	 lesions
10




PR,	1	VGPR).	The	 independently	assessed	responses	were	very	similar	 to	 the	 investigator	assessed	




20·47)	 and	 12	 month	 PFS	 was	 75·4%	 (95%	 CI	 56·7-86·8).	 PFS	 at	 12	 months	 was	 91·3%	 for	 those	




17·2mg	 (86·2%	 of	 the	 20mg	 planned	 dose).	 Nineteen	 (41·3%)	 patients	 required	 at	 least	 one	 dose	
reduction	and	 five	 (10·9%)	 received	at	 least	one	cycle	without	panobinostat.	The	reasons	 for	dose	
reductions	 were:	 ≥grade	 2	 non-haematological	 toxicity	 (8/19,	 42·1%),	 AST/ALT	 levels	 ≥	 5	 x	 upper	
limit	 (3/19,	 15·8%),	 grade	 3-4	 haematological	 toxicity	 (5/19,	 26·3%),	 other	 (10/19,	 52·6%).	 Seven	
(15·2%)	patients	received	at	 least	one	dose	reduction	due	to	a	GI	toxicity.	Twenty	(43·5%)	patients	




dexamethasone	 dose	 reduction	 with	 a	 mean	 dose	 of	 18·7mg	 (90·4%	 of	 the	 intended	 20mg)	






Adverse	 events	 reported	 in	 ≥10%	 of	 patients	 irrespective	 of	 causality	 are	 detailed	 in	 Table	 4.	 The	
commonest	 ≥grade	 3	 toxicities	 in	 the	 safety	 population	 (n=57)	 were	 neutrophil	 count	 reduced	
(26·4%),	 hypophosphatemia	 (19·3%),	 platelet	 count	 decreased	 (14·1%),	 raised	 alanine	
aminotransferase	(7·0%),	diarrhoea	(7·0%,	grade	3	only)	and	upper	respiratory	tract	infection	(7·0%).	
The	 commonest	 all	 grade	 toxicities	 were	 fatigue	 (89·5%)	 peripheral	 sensory	 neuropathy	 (77·2%),	




the	 analysis	 was	 9·3	 (range	 3-16).	 four	 patients	 (26·7%)	 completed	 one	 year	 of	 maintenance,	 six	
10	
	
stopped	 due	 to	 disease	 progression	 and	 one	 withdrew	 consent	 for	 further	 treatment	 due	 to	




This	 phase	 I/II	 study	 demonstrated	 that	 panobinostat	 at	 20mg	 can	 be	 safely	 given	 in	 combination	
with	VTD	for	patients	with	relapsed	MM.	Response	rates	were	high	(ORR	91%,	≥	VGPR	45·6%)	and	
similar	according	to	prior	bortezomib	exposure,	suggesting	effectiveness	of	this	as	a	“bortezomib	re-
treat”	 regimen.	As	expected,	 those	 treated	earlier	 in	 their	disease	 responded	better	 than	 those	at	
later	relapse	(≥VGPR	rates:	54·1%	(1	prior	line)	vs	11·1%	(≥2	prior	lines)).	Whilst	the	numbers	in	the	











16)	 for	 ASCT.	 As	 two	 doses	 of	 s.c.	 bortezomib	 were	 administered	 per	 cycle,	 the	 tolerability	 of	 the	
regimen	 was	 good	 and	 patients	 remained	 on	 study	 deepening	 response	 with	 time,	 in	 fact	 one	
patient	 achieved	 a	 VGPR	 after	 cycle	 11.	 Treatment	 was	 well	 tolerated	 with	 only	 two	 patients	
withdrawing	 consent	 due	 to	 toxicity	 (PANORAMA	 1,	 36%	 patients	 discontinued	 due	 to	 adverse	
events
1
).	 The	 majority	 of	 AEs	 were	 grade	 1-2	 with	 low	 rates	 of	 grade	 3-4	 diarrhoea	 and	 fatigue.	
Panobinostat	 maintenance	 was	 well	 tolerated	 and	 feasible.	 Fifteen	 patients	 commenced	
maintenance	 with	 four	 ongoing	 at	 the	 time	 of	 this	 report.	 Four	 patients	 completed	 16	 cycles	 of	




















only	 2	 doses	 per	 3	 weeks	 improved	 the	 overall	 toxicity	 profile.	 The	 incorporation	 of	 low	 dose	
thalidomide	 (≤100mg)	 is	 likely	 to	 have	 increased	 the	 efficacy	 and	 may	 in	 fact	 have	 reduced	 the	













patients	 were	 better	 as	 all	 were	 bortezomib	 naïve,	 none	 refractory	 to	 therapy,	 all	 had	 received	
previous	ASCT	and	received	a	total	of	48	doses	of	V.	 	This	compared	to	58·7%	receiving	prior	ASCT	
and	a	total	of	32	doses	of	V	given	in	MUK	six.	




of	 67%	 in	 a	 more	 heavily	 pre-treated	 population	 (median	 of	 five	 prior	 lines).	 However,	 whilst	 the	
MTD	was	determined	to	be	30mg,	the	authors	recommended	the	20mg	dose	should	be	investigated	
further.	 In	 comparison	 to	 many	 other	 new	 treatments,	 VTD	 is	 comparatively	 cost-effective	
particularly	 as	 bortezomib	 will	 soon	 be	 off	 patent.	 Therefore	 the	 VTD-P	 regimen	 is	 likely	 to	 be	 an	









As	 the	treatment	paradigm	for	MM	continues	 to	evolve	and	new	classes	of	drugs	are	approved,	 it	
remains	 crucial	 to	 maintain	 long	 term	 tolerability	 with	 multi-agent	 regimens.	 The	 MUK	 six	 trial	
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Days 1 and 8 
Thalidomide 
(oral) 
Days 1 - 21 
Dexamethasone 
(oral)  
Days 1, 2, 8 and 9 
Panobinostat (oral) 




 100 mg/day* 20 mg 10 mg 
2 1·3 mg/m
2 
100 mg/day* 20 mg 15 mg 
3 1·3 mg/m
2 















Median (Range)	 61·0 (41·0, 76·0) 60·5 (41·0, 76·0) 
Sex   
   Male 34 (59·6) 27 (58·7) 
   Female 23 (40·4) 19 (41·3) 
ECOG	Performance	Status   
   0 26 (45·6) 22 (47·8) 
   1 26 (45·6) 21 (45·7) 
   2 3 (5·3) 2 (4·3) 
Missing 2 (3·5) 1 (2·2) 
ISS   
   1 32 (56·1) 28 (60·9) 
   2 16 (28·1) 13 (28·3) 
   3 6 (10·5) 3 (6·5) 
Missing 3 (5·3) 2 (4·3) 
Prior	Lines	   
1 43 (75·4) 37 (80·4) 
15	
	
2 6 (10·5) 5 (10·9) 
3 5 (8·8) 1 (2·2) 
4 
3 (5·3) 3 (6·5) 
Prior	bortezomib	
  
No 19 (33·3) 13 (28·3) 
Yes 38 (66·7) 33 (71·7) 
Prior	IMiD	
  
No 23 (40·4) 22 (47·8) 
Yes 34 (59·6) 24 (52·2) 
EMA	population*	
  
No 45 (78·9) 38 (82·6) 
Yes 12 (21·1) 8 (17·4) 
Time	 from	diagnosis	 to	 registration	
(months)	)include	partial	dates**	
  
Mean (SD) 43·8 (28·43) 40·6 (28·36) 
Median (Range) 33·2 (11·8, 148·0) 30·8 (11·8, 148·0) 
Missing 10 8 
*  at least 2 prior lines of therapy including bortezomib and an IMiD 
























42	(91·3)	 21	(45·7)	 3	(6·5)	 18	(39·1)	 21	(45·7)	 2	(4·3)	 2	(4·3)	
1	prior	line	
(N=37)	
35	(94·6)	 20	(54·1)	 3	(8·1)	 17	(45·9)	 15	(40·5)	 0	(0·0)	 0	(0·0)	
>1	 prior	
lines	(n=9)	
7	(77·8)	 1	(11·1)	 0	(0·0)	 1	(11·1)	 6	(66·7)	 2	(22·2)	 0	(0·0)	
Prior	 BZ	
(N=33)	
30	(90·9)	 15	(45·5)	 2	(6·1)	 13	(39·4)	 15	(45·5)	 2	(6·1)	 1	(3·0)	
BZ	 naïve	
(N=13)	
12	(92·3)	 6	(46·2)	 1	(7·7)	 5	(38·5)	 6	(46·2)	 0	(0·0)	 1	(7·7)	
Prior	 IMiD	
(N=24)	
21	(87·5)	 9	(37·5)	 1	(4·2)	 8	(33·3)	 12	(50·0)	 2	(8·3)	 1	(4·2)	
IMid	 naïve	
(N=22)	


































Fatigue	 51	(89·5)	 36	(63·2)	 13	(22·8)	 2	(3·5)	 	
Peripheral	sensory	
neuropathy	
44	(77·2)	 41	(71·9)	 3	(5·3)	 	 	
Diarrhoea	 38	(66·7)	 26	(45·6)	 7	(12·3)	 4	(7)	 	
Constipation	 36	(63·2)	 30	(52·6)	 6	(10·5)	 	 	
Bone	pain	 35	(61·4)	 26	(45·6)	 7	(12·3)	 	 	
Nausea	 26	(45·6)	 23	(40·4)	 3	(5·3)	 	 	
Back	pain	 25	(43·9)	 18	(31·6)	 7	(12·3)	 	 	
Upper	respiratory	
infection	
24	(42·1)	 16	(28·1)	 2	(3·5)	 4	(7)	 	
Edema	limbs	 23	(40·4)	 22	(38·6)	 1	(1·8)	 	 	
Neutrophil	count	
decreased	
22	(38·6)	 4	(7)	 3	(5·3)	 12	(21·1)	 3	(5·3)	
Tremor	 22	(38·6)	 19	(33·3)	 2	(3·5)	 1	(1·8)	 	
Anemia	 21	(36·8)	 7	(12·3)	 11	(19·3)	 3	(5·3)	 	
Dyspnea	 20	(35·1)	 15	(26·3)	 3	(5·3)	 1	(1·8)	 	
Hypophosphatemia	 19	(33·3)	 1	(1·8)	 7	(12·3)	 10	(17·5)	 1	(1·8)	
Platelet	count	
decreased	
19	(33·3)	 6	(10·5)	 5	(8·8)	 3	(5·3)	 5	(8·8)	
Somnolence	 19	(33·3)	 19	(33·3)	 	 	 	
Dizziness	 18	(31·6)	 12	(21·1)	 5	(8·8)	 	 	
Creatinine	
increased	
16	(28·1)	 10	(17·5)	 5	(8·8)	 1	(1·8)	 	
	Myalgia	 15	(26·3)	 14	(24·6)	 1	(1·8)	 	 	
Cough	 14	(24·6)	 14	(24·6)	 	 	 	
Rash	maculo-
papular	
14	(24·6)	 11	(19·3)	 3	(5·3)	 	 	
Anorexia	 12	(21·1)	 11	(19·3)	 1	(1·8)	 	 	
Dysgeusia	 11	(19·3)	 10	(17·5)	 1	(1·8)	 	 	
18	
	
Fever	 11	(19·3)	 6	(10·5)	 3	(5·3)	 1	(1·8)	 	
Hypocalcemia	 11	(19·3)	 7	(12·3)	 4	(7)	 	 	
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